Get the Stockscreener App
26.72
2.85%
0.74
After Hours:
26.72
Arvinas Inc Stock (ARVN) Latest News
Braidwell LP Boosts Stock Position in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Investors to Connect - AccessWire
Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Stockholders to Inquire about Securities Investigation - AccessWire
Investors Still Waiting For A Pull Back In Arvinas, Inc. (NASDAQ:ARVN) - Simply Wall St
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Investors to Learn More About the Investigation - AccessWire
Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
Arvinas, Inc. (NASDAQ:ARVN) Stock Holdings Lessened by Victory Capital Management Inc. - Defense World
Arvinas to Present at Piper Sandler Healthcare Conference; Leadership to Share Updates | ARVN Stock News - StockTitan
BMO keeps Outperform rating on Arvinas shares, excited about vepdegestrant's progress - Investing.com
Arvinas, Inc. (ARVN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc.ARVN - PR Newswire
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium - GlobeNewswire
Arvinas to Present New Vepdegestrant Breast Cancer Treatment Data at SABCS 2024 | ARVN Stock News - StockTitan
Arvinas, Inc. (ARVN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - AccessWire
Algert Global LLC Buys 123,613 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Stockholders to Learn More About the Investigation - AccessWire
FY2025 EPS Estimates for Arvinas Decreased by Analyst - Defense World
Metastatic Prostate Cancer Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Merck, Arvinas Androgen Receptor, Novartis, UNICANCER, Aragon Pharma, Mark Stein - Barchart
Pfizer, Arvinas delay late-stage trial for breast cancer therapy - MSN
Metastatic Prostate Cancer Market to Show Remarkable Growth - openPR
Leerink Partnrs Brokers Lower Earnings Estimates for Arvinas - MarketBeat
BMO Capital Markets Lowers Arvinas (NASDAQ:ARVN) Price Target to $88.00 - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Investors to Reach Out - AccessWire
(ARVN) Technical Pivots with Risk Controls - Stock Traders Daily
Arvinas stock remains a Top Pick despite slight reduction in price target, says BMO - Investing.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Stockholders to Reach Out - AccessWire
Unveiling 4 Analyst Insights On Arvinas - Benzinga
Arvinas shares target cut to $62 on delayed trial data - Investing.com India
Arvinas (NASDAQ:ARVN) Coverage Initiated at Stephens - Defense World
Arvinas shares target cut to $62 on delayed trial data By Investing.com - Investing.com Nigeria
10 Best Small-Cap Stocks Ready To Explode - Insider Monkey
Arvinas, Inc. (NASDAQ:ARVN) Short Interest Update - Defense World
Arvinas reports delay in breast cancer trial results - Investing.com India
Arvinas reports delay in breast cancer trial results By Investing.com - Investing.com UK
Arvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To Explode - Insider Monkey
Arvinas (NASDAQ:ARVN) Now Covered by Stephens - MarketBeat
Short Interest in Arvinas, Inc. (NASDAQ:ARVN) Drops By 5.6% - MarketBeat
Stephens & Co. Initiates Coverage of Arvinas (ARVN) with Overweight Recommendation - MSN
RTW INVESTMENTS, LP Adjusts Stake in Arvinas Inc - GuruFocus.com
Arvinas chief accounting officer David Loomis sells $10,300 in stock By Investing.com - Investing.com Australia
Arvinas chief accounting officer David Loomis sells $10,300 in stock - Investing.com
How the (ARVN) price action is used to our Advantage - Stock Traders Daily
Arvinas, Inc. (NASDAQ:ARVN) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Arvinas, Inc. (NASDAQ:ARVN) Receives $56.92 Consensus Target Price from Analysts - MarketBeat
Arvinas (ARVN) Stock Price, News & Analysis - MarketBeat
Arvinas's SWOT analysis: biotech stock poised for pivotal trial results - Investing.com India
Arvinas's SWOT analysis: biotech stock poised for pivotal trial results By Investing.com - Investing.com Canada
Allspring Global Investments Holdings LLC Has $182,000 Stake in Arvinas, Inc. (NASDAQ:ARVN) - Defense World
Arvinas to Participate in Upcoming Investor Conferences - GlobeNewswire
Arvinas (NASDAQ:ARVN) Receives Buy Rating from HC Wainwright - Defense World
FY2024 EPS Estimates for Arvinas Reduced by Leerink Partnrs - MarketBeat
Wedbush Issues Pessimistic Estimate for Arvinas Earnings - Defense World
FY2024 EPS Estimates for Arvinas Cut by Leerink Partnrs - Defense World
Arvinas (NASDAQ:ARVN) Price Target Lowered to $40.00 at Oppenheimer - Defense World
Arvinas Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Oppenheimer cuts Arvinas shares price target to $40 ahead of TACTIVE-U trial - Investing.com
Arvinas' (ARVN) Buy Rating Reiterated at HC Wainwright - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Q3 2024 Earnings Call Transcript - Insider Monkey
Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates - MSN
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):